We are leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 15 years of experience. Our understanding of the complex pathways and molecular mechanisms of this disease has enabled the development of tailored medicines that can make a real difference to patient outcomes.
We are set to continue our leadership in the field of PAH into the mid-2020s, thanks to our assets Veletri® (epoprostenol), Opsumit® (macitentan), and Uptravi® (selexipag).
Our expertise in human biology, especially our knowledge of specific families of molecular targets, such as G-Protein Coupled Receptors, led us to Opsumit and it is this knowledge that will take us to new areas.
We leverage our scientific expertise through in-house discovery, development and marketing talents; ‘fully-integrated’ also means that we have all the expertise in all areas of the value chain for delivering great products to physicians, patients, payors – as well as all the support functions and infrastructure needed to deliver our ambition efficiently.